Chong Kun Dang Pharmaceutical Corp.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-01-01

Employees: 2.3K

Market Cap: -

Website: http://www.ckdpharm.com

Clinical Trials

Efficacy and Safety of Lobeglitazone Versus Sitagliptin

Phase 4

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Lobelitazone 0.5mg
Drug: Sitagliptin 100mg

First Posted Date: 2015-06-24

Last Posted Date: 2015-07-08

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 248

Registration Number: NCT02480465

Locations: 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of

CKD-391 Pharmacokinetic Study

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CKD-391
Drug: Atrovastatin and Ezetimibe combination therapy

First Posted Date: 2015-06-03

Last Posted Date: 2016-10-17

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 52

Registration Number: NCT02461004

Locations: 🇰🇷
The Korea University Anam Hospital, Seoul, Korea, Republic of

Clinical Trial to Evaluate the Efficacy and Safety of CKD-391

Phase 3

Completed

Conditions: Hyperlipidemia

Interventions: Drug: Atorvastatin40mg, Ezetimibe placebo
Drug: Atorvastatin10mg, Ezetimibe10mg
Drug: Atorvastatin10mg, Ezetimibe placebo
Drug: Atorvastatin20mg, Ezetimibe10mg
Drug: Atorvastatin20mg, Ezetimibe placebo
Drug: Atorvastatin40mg, Ezetimibe10mg

First Posted Date: 2015-05-21

Last Posted Date: 2016-01-28

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 385

Registration Number: NCT02451098

Locations: 🇰🇷
The catholic university of korea seoul st. Mary's hospital, Seoul, Korea, Republic of

CKD-337(2) Drug-drug Interaction Study

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lipitor Tab. 40mg
Drug: Trilipix 135mg

First Posted Date: 2015-04-21

Last Posted Date: 2017-08-08

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 30

Registration Number: NCT02422030

Locations: 🇰🇷
Chonbuk National University Hospital, Deokjin-gu, Jeonju-si, Jeollabuk-do, Korea, Republic of

CKD-828 (80/5mg) Pharmacokinetic Study

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: CKD-828
Drug: Telmisartan
Drug: S-amlodipine

First Posted Date: 2015-02-09

Last Posted Date: 2015-07-08

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 48

Registration Number: NCT02358824

Locations: 🇰🇷
Kyungpook National University Hospital, Daegu, samdeok-dong, 2-ga 50, samdeok-dong, 2-ga 50 Jung-gu, Korea, Republic of

Efficacy and Safety of Eupasidin-s Tab.(EUPASIDIN-S) in Gastritis Patients

Phase 4

Completed

Conditions: Chronic Gastritis
Acute Gastritis

Interventions: Drug: Stillen Tab.
Drug: Eupasidin-s Tab

First Posted Date: 2015-02-05

Last Posted Date: 2015-08-24

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 230

Registration Number: NCT02356679

Locations: 🇰🇷
Inje University Busanpaik hospital, Busan, Busangjin, Korea, Republic of
🇰🇷
Chonbuk National University Hospital, Jeonju, Deokjin-gu, Korea, Republic of
🇰🇷
Wonju Severance Christian Hospital, Wonju, Ilsan-ro, Korea, Republic of

and more 7 locations

Tacrobell tab_Phase1_PK

Phase 1

Completed

Conditions: Immunosuppressant(Organ Transplantation, RA)

Interventions: Drug: Prograf cap. 2mg
Drug: Tacrobell tab. 2mg

First Posted Date: 2015-01-13

Last Posted Date: 2017-08-08

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 50

Registration Number: NCT02336854

CKD-391 DDI : Atorvastatin and Ezetimibe in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 1 (Lipitor®)
Drug: 2 (Ezetrol®)
Drug: 4 (Lipitor®)
Drug: 3(Lipitor®, Ezetrol®)
Drug: 5 (Ezetrol®)
Drug: 6(Lipitor®, Ezetrol®)
Drug: 1 (Ezetrol®)
Drug: 5 (Lipitor®)
Drug: 2(Lipitor®, Ezetrol®)
Drug: 3 (Lipitor®)
Drug: 4(Lipitor®, Ezetrol®)
Drug: 6 (Ezetrol®)
Drug: 1 (Lipitor®, Ezetrol®)
Drug: 2 (Lipitor®)
Drug: 3 (Ezetrol®)
Drug: 4 (Ezetrol®)
Drug: 5 (Lipitor®, Ezetrol®)
Drug: 6 (Lipitor®)

First Posted Date: 2014-11-11

Last Posted Date: 2015-03-10

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 36

Registration Number: NCT02288338

Locations: 🇰🇷
ChongKunDang, Seoul, Korea, Republic of

CKD-828 (80/5mg) Pharmacokinetic Study

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: CKD-828
Drug: Telmisartan
Drug: S-amlodipine

First Posted Date: 2014-09-26

Last Posted Date: 2015-04-10

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 69

Registration Number: NCT02250833

Locations: 🇰🇷
Kyungpook National University Hospital, Daegu, samdeok-dong, 2-ga 50, samdeok-dong, 2-ga 50 Jung-gu, Korea, Republic of

CKD-397 Drug-drug Interaction Study (B)

Phase 1

Completed

Conditions: Healty Male Volunteers

Interventions: Drug: Harnal-D Cap. 0.2mg
Drug: Cialis Tab. 5mg

First Posted Date: 2014-09-25

Last Posted Date: 2015-08-20

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 29

Registration Number: NCT02247505

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju-si, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy